Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie,
Medizinische Klinik und Poliklinik II,
Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II
Hermann Einsele has not added Biography.
If you are Hermann Einsele and would like to personalize this page please email our Author Liaison for assistance.
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan, 2009 | Pubmed ID: 19029417
Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
Haematologica Jan, 2009 | Pubmed ID: 19066334
The temporal dynamics of differential gene expression in Aspergillus fumigatus interacting with human immature dendritic cells in vitro.
PloS one Jan, 2011 | Pubmed ID: 21264256
Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-γ release.
Journal of immunology (Baltimore, Md. : 1950) Aug, 2011 | Pubmed ID: 21697457
Molecular techniques in the diagnosis of deep and systemic mycosis.
Clinics in dermatology , 2012 | Pubmed ID: 23068152
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb, 2014 | Pubmed ID: 24297946
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice.
Immunology and cell biology Sep, 2014 | Pubmed ID: 24820384
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Haematologica Sep, 2014 | Pubmed ID: 24837466
Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Aug, 2014 | Pubmed ID: 24850801
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec, 2014 | Pubmed ID: 25385737
Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb, 2015 | Pubmed ID: 25547501
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.
EMBO molecular medicine Mar, 2015 | Pubmed ID: 25736399
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
The New England journal of medicine Aug, 2015 | Pubmed ID: 26035255
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
The Lancet. Oncology Dec, 2015 | Pubmed ID: 26549589
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Mar, 2016 | Pubmed ID: 26551637
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Feb, 2016 | Pubmed ID: 26564323
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
British journal of haematology Mar, 2016 | Pubmed ID: 26771088
Proteomic Profiling of Serological Responses to Aspergillus fumigatus Antigens in Patients with Invasive Aspergillosis.
Journal of proteome research May, 2016 | Pubmed ID: 26974881
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation.
European journal of cancer (Oxford, England : 1990) Jul, 2016 | Pubmed ID: 27185572
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Haematologica Nov, 2016 | Pubmed ID: 27662018
Myeloma CARs are rolling into the clinical arena.
Blood Sep, 2016 | Pubmed ID: 27688779
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.
Blood Jun, 2017 | Pubmed ID: 28476749
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 normal lymphocytes.
Blood Dec, 2017 | Pubmed ID: 29089311
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
American journal of hematology Mar, 2018 | Pubmed ID: 29178361
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
The New England journal of medicine Dec, 2017 | Pubmed ID: 29211658
Human and Murine Innate Immune Cell Populations Display Common and Distinct Response Patterns during Their Interaction with the Pathogenic Mold .
Frontiers in immunology , 2017 | Pubmed ID: 29270175
CAR T-cells targeting FLT3 have potent activity against FLT3ITD AML and act synergistically with the FLT3-inhibitor crenolanib.
Leukemia May, 2018 | Pubmed ID: 29472720
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Jan, 2019 | Pubmed ID: 29777009
Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
Blood advances Aug, 2018 | Pubmed ID: 30154125
CAR T cells targeting αβ integrin are effective against advanced cancer in preclinical models.
Advances in cell and gene therapy Sep, 2018 | Pubmed ID: 30420973
Immunomodulation as a Therapy for Infection: Current Status and Future Perspectives.
Journal of fungi (Basel, Switzerland) Dec, 2018 | Pubmed ID: 30558125
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Journal of immunotherapy (Hagerstown, Md. : 1997) Jun, 2019 | Pubmed ID: 31090657
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
Science translational medicine Jul, 2019 | Pubmed ID: 31270272
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.
Nature communications Jul, 2019 | Pubmed ID: 31316055
mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.
Haematologica May, 2020 | Pubmed ID: 31413097
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
JCI insight Sep, 2019 | Pubmed ID: 31415244
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.
Bone marrow transplantation Aug, 2019 | Pubmed ID: 31431702
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Leukemia Nov, 2019 | Pubmed ID: 31462732
A highly soluble Sleeping Beauty transposase improves control of gene insertion.
Nature biotechnology 12, 2019 | Pubmed ID: 31685959
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Haematologica , 2020 | Pubmed ID: 31753925
β-.
Journal for immunotherapy of cancer Apr, 2020 | Pubmed ID: 32303620
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Leukemia Jan, 2021 | Pubmed ID: 32350373
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
Journal for immunotherapy of cancer May, 2020 | Pubmed ID: 32474415
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects.
Leukemia & lymphoma Oct, 2020 | Pubmed ID: 32476543
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood Aug, 2020 | Pubmed ID: 32496541
Inefficient CAR-proximal signaling blunts antigen sensitivity.
Nature immunology 08, 2020 | Pubmed ID: 32632291
What is the future of immunotherapy in multiple myeloma?
Blood Nov, 2020 | Pubmed ID: 32735639
Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
Current opinion in oncology Sep, 2020 | Pubmed ID: 32740095
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Blood cancer journal Sep, 2020 | Pubmed ID: 32887873
Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies.
HemaSphere Aug, 2020 | Pubmed ID: 32904089
BATF3 programs CD8 T cell memory.
Nature immunology Nov, 2020 | Pubmed ID: 32989328
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Oncology research and treatment , 2020 | Pubmed ID: 33099551
Polymorphisms within the and Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium.
Journal of fungi (Basel, Switzerland) Dec, 2020 | Pubmed ID: 33374839
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of mutations - a registry based analysis.
Leukemia & lymphoma Jun, 2021 | Pubmed ID: 33399480
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Leukemia Sep, 2021 | Pubmed ID: 33603142
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future.
HemaSphere Feb, 2021 | Pubmed ID: 33880433
Loss-of-Function Mutations of Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.
Cancers Apr, 2021 | Pubmed ID: 33926021
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.
Bone marrow transplantation Oct, 2021 | Pubmed ID: 33976382
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
European journal of haematology Nov, 2021 | Pubmed ID: 34270825
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Blood Nov, 2021 | Pubmed ID: 34289026
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Blood Jan, 2022 | Pubmed ID: 34320176
[Vorwort].
Oncology research and treatment , 2021 | Pubmed ID: 34344011
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Blood advances Sep, 2021 | Pubmed ID: 34459887
Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Transplantation and cellular therapy Jun, 2022 | Pubmed ID: 34757220
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Blood advances Mar, 2022 | Pubmed ID: 34794176
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.
Cancers Dec, 2021 | Pubmed ID: 34944782
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
Blood cancer journal Feb, 2022 | Pubmed ID: 35210399
Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT.
Bone marrow transplantation May, 2022 | Pubmed ID: 35332305
Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Bone marrow transplantation Jul, 2022 | Pubmed ID: 35523848
[Monoclonal gammopathy of (un)known significance].
Deutsche medizinische Wochenschrift (1946) Jun, 2022 | Pubmed ID: 35636418
[Vorwort des DGHO-Vorstandes].
Oncology research and treatment , 2022 | Pubmed ID: 35871509
[Klinische Studien in der Hämatologie und Onkologie].
Oncology research and treatment , 2022 | Pubmed ID: 35871514
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Journal of hematology & oncology Sep, 2022 | Pubmed ID: 36064577
Adjusted comparison of outcomes between patients from CARTITUDE-1 multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica Aug, 2023 | Pubmed ID: 36546453
All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
Haematologica Feb, 2023 | Pubmed ID: 36722406
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Advances in therapy May, 2023 | Pubmed ID: 36961654
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.
Blood cancer journal May, 2023 | Pubmed ID: 37236968
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
The New England journal of medicine Jul, 2023 | Pubmed ID: 37272512
Venetoclax salvage therapy in relapsed/refractory multiple myeloma.
Haematologica Mar, 2024 | Pubmed ID: 37794827
CAR T-cell therapy in multiple myeloma: mission accomplished?
Blood Jan, 2024 | Pubmed ID: 38033289
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Advances in therapy Feb, 2024 | Pubmed ID: 38110653
Bispecific Antibodies in the Treatment of Multiple Myeloma.
Hematology/oncology clinics of North America Apr, 2024 | Pubmed ID: 38199897
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Advances in therapy Apr, 2024 | Pubmed ID: 38402374
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
The Lancet. Oncology May, 2024 | Pubmed ID: 38697166
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Signal transduction and targeted therapy Aug, 2024 | Pubmed ID: 39138146
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.
Cellular oncology (Dordrecht, Netherlands) Aug, 2024 | Pubmed ID: 39192092
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis).
Leukemia Sep, 2024 | Pubmed ID: 39322709
Sporadic late onset nemaline myopathy and immunoglobulin deposition disease.
Muscle & nerve Dec, 2013 | Pubmed ID: 23873431
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Blood Dec, 2015 | Pubmed ID: 26480933
Common Genetic Polymorphisms within NFκB-Related Genes and the Risk of Developing Invasive Aspergillosis.
Frontiers in microbiology , 2016 | Pubmed ID: 27570521
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.
Theranostics , 2017 | Pubmed ID: 28529638
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.
Molecular therapy : the journal of the American Society of Gene Therapy Feb, 2019 | Pubmed ID: 30573301
Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician.
Journal of clinical medicine Jun, 2019 | Pubmed ID: 31226876
Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.
Leukemia & lymphoma Dec, 2019 | Pubmed ID: 31317812
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Journal of cancer research and clinical oncology Jan, 2022 | Pubmed ID: 34085097
Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Leukemia Jan, 2022 | Pubmed ID: 34845317
A Clinical Case of COVID-19-Associated Pulmonary Aspergillosis (CAPA), Illustrating the Challenges in Diagnosis (Despite Overwhelming Mycological Evidence).
Journal of fungi (Basel, Switzerland) Jan, 2022 | Pubmed ID: 35050021
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Leukemia May, 2022 | Pubmed ID: 35332278
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Haematologica Jan, 2023 | Pubmed ID: 35678031
Highjacking myeloma's niche with beefed-up CAR-Ts.
Blood Jun, 2022 | Pubmed ID: 35771562
CAR T cells targeting are effective at treating invasive pulmonary aspergillosis in preclinical models.
Science translational medicine Sep, 2022 | Pubmed ID: 36170447
[Vorwort des DGHO-Vorstands].
Oncology research and treatment , 2023 | Pubmed ID: 37748445
BCMA CAR-T cells in multiple myeloma-ready for take-off?
Leukemia & lymphoma Feb, 2024 | Pubmed ID: 37997705
Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Future oncology (London, England) Aug, 2024 | Pubmed ID: 39110421
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database.
Blood advances Oct, 2024 | Pubmed ID: 39110988
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma.
Blood Aug, 2024 | Pubmed ID: 39172759
Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML.
Blood advances Sep, 2024 | Pubmed ID: 39293081
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved